Publications by authors named "Kai-Qi Lan"
Article Synopsis
- The study investigates the effects of the PD-1 inhibitor toripalimab combined with chemoradiotherapy on patients with advanced nasopharyngeal carcinoma, particularly those with high EBV DNA levels, to see if it reduces recurrence risk compared to placebo.* -
- Conducted at Sun Yat-sen University Cancer Centre in China, 150 eligible patients were randomly assigned to receive either toripalimab or a placebo before and after chemoradiotherapy, focusing on the 2-year progression-free survival rate as the main outcome measure.* -
- Initial findings suggest that most of the participants were male (77%), and by the latest follow-up, the median progression-free survival period was approximately 37.8 months,
Article Synopsis
- - A study developed a nomogram to predict progression-free survival (PFS) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) undergoing anti-PD-1 treatment, using various health indicators and validated it with separate patient groups.
- - Key factors included liver metastasis, albumin levels, lactate dehydrogenase, and Epstein-Barr virus DNA, which accurately categorized patients into favorable or unfavorable prognosis groups based on their PFS outcomes.
- - The model showed significant differences in survival rates and treatment responses between the prognosis groups, making it a useful tool for estimating individual benefits from immunotherapy.
Background And Purpose: We sought to determine the prognostic value of a pre-treatment peripheral blood signature and the peripheral blood signature-based nomogram for patients with non-metastatic nasopharyngeal carcinoma (NPC).
Materials And Methods: We retrospectively collected 21 peripheral blood indicators from patients with NPC between 2004 and 2015. Data were randomly divided into a training and a validation set (ratio: 6:4).